Copland, Mhairi, Ariti, Cono ORCID: https://orcid.org/0000-0001-7615-0935, Thomas, Ian F., Upton, Laura, Sydenham, Mia, Mehta, Priyanka, Islam, Shahid, Kjeldsen, Lars, Burnett, Alan K., Hills, Robert K. ORCID: https://orcid.org/0000-0003-0166-0062, Russell, Nigel, Dennis, Mike and UK NCRI AML Study Group 2024. A randomised evaluation of low‐dose cytosine arabinoside plus lenalidomide versus single‐agent low‐dose cytosine arabinoside in older patients with acute myeloid leukaemia: Results from the LI ‐1 trial. British Journal of Haematology 204 (3) , pp. 871-876. 10.1111/bjh.19220 |
PDF
- Published Version
Available under License Creative Commons Attribution. Download (538kB) |
Abstract
Summary: Improving outcomes for older patients with acute myeloid leukaemia remains an unmet need. As part of the LI‐1 trial, we evaluated lenalidomide (LEN) in combination with low‐dose cytosine arabinoside (LDAC) in patients aged >60 years unfit for intensive therapy and compared this to LDAC alone. Two hundred and two patients, randomised 1:1, were evaluable. Overall response rate (CR + CRi) was higher for LDAC + LEN versus LDAC (26% and 13.7% respectively p = 0.031). However, there was no difference in overall survival between the arms (14% and 11.5% at 2 years for LDAC + LEN and LDAC respectively). The addition of LEN was associated with increased toxicity and supportive care requirements.
Item Type: | Article |
---|---|
Date Type: | Publication |
Status: | Published |
Schools: | Medicine Centre for Trials Research (CNTRR) |
Additional Information: | License information from Publisher: LICENSE 1: URL: http://creativecommons.org/licenses/by/4.0/ |
Publisher: | Wiley |
ISSN: | 0007-1048 |
Date of First Compliant Deposit: | 29 November 2023 |
Date of Acceptance: | 10 November 2023 |
Last Modified: | 18 Apr 2024 13:32 |
URI: | https://orca.cardiff.ac.uk/id/eprint/164444 |
Actions (repository staff only)
Edit Item |